Conducting the metabolic syndrome orchestra.

Department of Human Genetics, the Department of Microbiology, Immunology and Molecular Genetics, and the Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Nature Genetics (Impact Factor: 29.65). 06/2011; 43(6):506-8. DOI: 10.1038/ng.842
Source: PubMed

ABSTRACT Genetic and gene expression studies have suggested an important role for KLF14 in metabolic disease. A new study now identifies a network of genes whose expression is associated with KLF14 variation in trans, providing a framework for understanding how KLF14 influences disease risk.


Available from: Mete Civelek, May 30, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Systems genetics is an approach to understand the flow of biological information that underlies complex traits. It uses a range of experimental and statistical methods to quantitate and integrate intermediate phenotypes, such as transcript, protein or metabolite levels, in populations that vary for traits of interest. Systems genetics studies have provided the first global view of the molecular architecture of complex traits and are useful for the identification of genes, pathways and networks that underlie common human diseases. Given the urgent need to understand how the thousands of loci that have been identified in genome-wide association studies contribute to disease susceptibility, systems genetics is likely to become an increasingly important approach to understanding both biology and disease.
    Nature Reviews Genetics 12/2013; DOI:10.1038/nrg3575 · 39.79 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sphingosine kinase 1 (SK1) is an FGF inducible gene responsible for generation of sphingosine 1 phosphate, a critical lipid signaling molecule implicated in diverse endothelial cell (EC) functions. In this study, we identified SK1 as a target of the canonical FGF2/FGFR1 activation pathway in EC and sought to identify novel transcriptional pathways that mediate lipid signaling. Studies using the 1.9 Kb SK1 promoter and deletion mutants revealed that basal and FGF2 stimulated promoter activity occurred through two GC-rich regions located within 633 bp of the transcription start site. Screening for GC rich binding transcription factors that could activate this site demonstrated that KLF14, a gene implicated in obesity and the metabolic syndrome, binds to this region. Congruently, overexpression of KLF14 increased basal and FGF2 stimulated SK1 promoter activity by 3 fold, and this effect was abrogated after mutation of the GC rich sites. In addition, KLF14 siRNA transfection decreased SK1 mRNA and protein levels by 3 fold. Congruently, SK1 mRNA and protein levels were decreased in livers from KLF14 knockout mice. Combined, luciferase, gel shift, and chromatin immunoprecipitation assays showed that KLF14 couples to p300 to increase the levels of histone marks associated with transcriptional activation (H4K8ac, and H3K14ac), while decreasing repressive marks (H3K9me3 and H3K27me3). Collectively, the results demonstrate a novel mechanism whereby SK1 lipid signaling is regulated by epigenetic modifications conferred by KLF14 and p300. Thus, this is the first description of the activity and mechanisms underlying the function of KLF14 as an activator protein and novel regulator of lipid signaling.
    Journal of Biological Chemistry 04/2014; 289(22). DOI:10.1074/jbc.M113.544346 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The function of Kruppel-like Factor 11 (KLF11) in the regulation of metabolic pathways is conserved from flies to human. Alterations in KLF11 function result in Maturity Onset Diabetes of the Young 7 (MODY7) and neonatal diabetes, however, the mechanisms underlying the role of this protein in metabolic disorders remain unclear. Here, we seek to investigate how the A347S genetic variant, present in MODY7 patients, modulates KLF11 transcriptional activity. A347S affects a previously identified transcriptional regulatory domain 3 (TRD3) for which co-regulators remain unknown. Structure-oriented sequence analyses, described here, predict that the KLF11 TRD3 represents an evolutionarily conserved protein domain. Combined, yeast two-hybrid and protein arrays demonstrate that the TRD3 binds WD40, WWI, WWII, and SH3-domain containing proteins. Using one of these proteins as a model, guanine nucleotide binding protein beta 2 (Gβ2), we investigate the functional consequences of KLF11 coupling to a TRD3 binding partner. Combined, immunoprecipitation and biomolecular fluorescence complementation assays confirm that activation of three different metabolic GPCR receptors (β-adrenergic, secretin and CCK) induce nuclear translocation of Gβ2 to directly bind KLF11 in a manner that is disrupted by the MODY7 A347S variant. Using genome-wide expression profiles, we identify metabolic gene networks impacted upon TRD3 disruption. Furthermore, A347S disrupts KLF11-mediated increases in basal insulin levels and promoter activity, combined with blunted glucose-stimulated insulin secretion. Thus, this study characterizes a novel protein-protein interaction domain disrupted in a KLF gene variant that associates to MODY7, contributing to our understanding of gene regulation events in complex metabolic diseases.
    Journal of Biological Chemistry 04/2013; 288(24). DOI:10.1074/jbc.M112.434670 · 4.60 Impact Factor